- Home
- NMAI vs ZVRA Comparison
NMAI vs ZVRA Comparison
Compare NMAI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | ZVRA |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.3M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NMAI | ZVRA |
|---|---|---|
| Price | $13.72 | $8.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 112.2K | ★ 642.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | 0.64 | ★ 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | $21.24 | ★ $7.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.21 | $6.19 |
| 52 Week High | $13.96 | $13.16 |
Technical Indicators
Market Signals| Indicator | NMAI | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 49.77 |
| Support Level | $12.72 | $8.61 |
| Resistance Level | $13.96 | $8.99 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 47.86 | 47.00 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.